Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Amgen Inc.. A complete text table follows the diagram.
Repatha, EVENITY and TEPEZZA expanded rapidly while Prolia, XGEVA and Enbrel contracted, leaving a diversified $8.2 billion product portfolio and a 20% R&D reinvestment rate
Swipe to explore
Named-product flows are directly reported. The remaining portfolio is the exact residual between total product sales and the eight displayed products. Other operating income is embedded in reported total operating expenses; other income is shown before net interest.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Repatha | 1 | $876M | Up 34% |
| Prolia | 1 | $727M | Down 34% |
| EVENITY | 1 | $562M | Up 27% |
| TEPEZZA | 1 | $490M | Up 29% |
| Otezla | 1 | $431M | Down 1% |
| BLINCYTO | 1 | $415M | Up 12% |
| Nplate | 1 | $412M | Up 32% |
| XGEVA | 1 | $411M | Down 27% |
| Remaining product portfolio | 1 | $3.9B | Nine named and other products |
| Partner, royalty & other revenue | 1 | $400M | Up 45% |
| Total revenue | 2 | $8.6B | Up 5.8% year over year |
| Other operating income | 2 | $113M | Reported net credit |
| Revenue plus operating credit | 3 | $8.7B | Resources before operating costs |
| Operating income | 4 | $2.7B | 30.9% operating margin |
| Cost of sales | 4 | $2.7B | Includes acquired-intangible amortization |
| Research & development | 4 | $1.7B | 20% of revenue |
| Selling, general & administrative | 4 | $1.6B | Commercial and corporate support |
| Other income | 4 | $75M | Net non-interest income |
| Income before interest | 5 | $2.7B | Operating plus other income |
| Income before tax | 6 | $2.1B | 24.2% of revenue |
| Net interest expense | 6 | $657M | Acquisition-heavy debt load |
| Net income | 7 | $1.8B | $3.37 diluted EPS |
| Income tax | 7 | $265M | 12.7% effective rate |
| From | To | Value |
|---|---|---|
| Repatha | Total revenue | $876M |
| Prolia | Total revenue | $727M |
| EVENITY | Total revenue | $562M |
| TEPEZZA | Total revenue | $490M |
| Otezla | Total revenue | $431M |
| BLINCYTO | Total revenue | $415M |
| Nplate | Total revenue | $412M |
| XGEVA | Total revenue | $411M |
| Remaining product portfolio | Total revenue | $3.9B |
| Partner, royalty & other revenue | Total revenue | $400M |
| Total revenue | Revenue plus operating credit | $8.6B |
| Other operating income | Revenue plus operating credit | $113M |
| Revenue plus operating credit | Operating income | $2.7B |
| Revenue plus operating credit | Cost of sales | $2.7B |
| Revenue plus operating credit | Research & development | $1.7B |
| Revenue plus operating credit | Selling, general & administrative | $1.6B |
| Operating income | Income before interest | $2.7B |
| Other income | Income before interest | $75M |
| Income before interest | Income before tax | $2.1B |
| Income before interest | Net interest expense | $657M |
| Income before tax | Net income | $1.8B |
| Income before tax | Income tax | $265M |